Johnson TB, et al. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15:161-178.
National Institutes of Health. Batten Disease Fact Sheet. Accessed July 27, 2021. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Batten-Disease-Fact-Sheet
US Food and Drug Administration. FDA approves first treatment for a form of Batten disease. Released April 27, 2017. Accessed July 27, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-form-batten-disease#
European Medicines Agency. Cerliponase alfa Product Information. Published June 22, 2017. Updated June 22, 2017. Accessed August 23, 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/brineura
Schulz A, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378:1898-1907.
Mole SE, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2018;18:107-116.
Kohlschütter A, et al. Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs. 2019;33:315-325.
Specchio N, et al. Neuronal ceroid lipofuscinosis: potential for targeted therapy. Drugs. 2021;81:101-123.
Mole SE, et al. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta. 2015;1852(10 Pt B):2237-2241.
Nelvagal HR, et al. An update on the progress of preclinical models for guiding therapeutic management of neuronal ceroid lipofuscinosis. Expert Opin Orphan Drugs. 2019;7:555-568.
Augustine EF, et al. Management of CLN1 Disease: International Clinical Consensus. Pediatr Neurol. 2021;120:38-51.
National Institutes of Health (NIH). CLN2 disease. Updated August 18, 2020. Accessed July 27, 2021. https://medlineplus.gov/genetics/condition/cln2-disease/
Nickel M, et al. Natural history of late infantile CLN2 disease: quantitative prospective assessment of disease characteristics and rate of progression in an international cohort of 140 patients. Lancet Child Adolesc Health. 2018;2:582-590.
Wibbeler E, et al. Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: a retrospective case series. J Child Neurol. 2020;36:468-474.
Schulz A, et al. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013;1832:1801-1806.
Simonati A, et al. Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5. Dev Med Child Neurol. 2017;59:815-821.
National Institutes of Health (NIH). CLN7 disease. Updated June 1, 2021. Accessed July 27, 2021. https://medlineplus.gov/genetics/condition/cln7-disease/
National Institutes of Health (NIH). CLN8 disease. Updated August 18, 2020. Accessed July 27, 2021. https://medlineplus.gov/genetics/condition/cln8-disease/
National Institutes of Health (NIH). CLN10 disease. Updated August 18, 2020. Accessed July 27, 2021. https://medlineplus.gov/genetics/condition/cln10-disease/
National Institutes of Health (NIH). CLN11 disease. Updated August 18, 2020. Accessed July 27, 2021. https://medlineplus.gov/genetics/condition/cln11-disease/
Orphanet. ATP13A2-related juvenile neuronal ceroid lipofuscinosis. Updated July 27, 2021. Accessed July 28, 2021. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=314632
Kohlschütter A, et al. Epilepsy in neuronal ceroid lipofuscinoses. J Ped Epilepsy. 2014;3:199-206.
Orphanet. Progressive myoclonic epilepsy type 3. Updated July 27, 2021. Accessed July 28, 2021. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=263516
Espitia Segura OM, et al. "Real world effectiveness of cerliponase alfa in classical and atypical patients. A case series." Mol Genet Metab Rep. 2021;27:100718.
ClinicalTrials.gov. A multicenter, multinational, extension study to evaluate the long-term efficacy and safety of BMN 190 in patients with CLN2 disease. Accessed July 28, 2021. https://clinicaltrials.gov/ct2/show/NCT02485899
ClinicalTrials.gov. A safety, tolerability, and efficacy study of intracerebroventricular BMN 190 in pediatric patients < 18 years of age with CLN2 disease. Accessed July 28, 2021. https://clinicaltrials.gov/ct2/show/NCT02678689
ClinicalTrials.gov. A multicenter, multi-national open-label program to provide BMN 190 to patients diagnosed with CLN2 disease. Accessed July 28, 2021. https://clinicaltrials.gov/ct2/show/NCT02963350
Masten MC, et al. Batten disease: an expert update on agents in preclinical and clinical trials. Expert Opin Investig Drugs. 2020;29:1317-1322.
Worgall S, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008;19:463-474.
Sondhi D, et al. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Sci Transl Med. 2020;12:eabb5413.
los Reyes E, et al. Single-dose AAV9-CLN6 gene transfer stabilizes motor and language function in CLN6-type Batten disease: interim results from the first clinical gene therapy trial. 16th International Child Neurology Virtual Congress. October 19-23, 2020. PL67. https://icnapedia.org/pdf/PLATFORM_ASSIGNMENTS_JICNA_2020_S1.pdf
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. A self-complementary adeno-associated virus serotype 9 expressing human codon-optimized CLN1 under control of CBh. Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=628718
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. Adeno-associated viral vector encoding the human ceroid lipofuscinosis neuronal type 2 (CLN2) gene. Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=825521
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. Non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1). Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=663718
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. Non-replicating recombinant, self-complementary adeno-associated virus serotype 9 containing the human CLN3 gene. Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=713119
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3). Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=570016
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. Adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene. Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=740020
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. Non-replicating recombinant, self-complementary adeno-associated virus serotype 9 containing the human CLN6 gene. Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=714419
US Food & Drug Administration. Search Orphan Drug Designations and Approvals. An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8. Accessed July 28, 2021. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=751620
Brondon J, et al. Outcomes of umbilical cord blood transplantation in children with Batten Disease. Stem Cells Transl Med. 2019;8(suppl 1):S12.
Batten Disease News. FDA Grants PLX-100 Orphan Drug Designation to Treat Batten Disease. Published December 12, 2017. Accessed July 28, 2021. https://battendiseasenews.com/2017/12/12/fda-grants-plx-100-orphan-drug-designation-to-treat-batten-disease/
Batten Disease News. PLX-200. Updated April 13, 2020. Accessed July 28, 2021. https://battendiseasenews.com/plx-200/
Palmieri M, et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun. 2017;8:14338.
ClinicalTrials.gov. A natural history study of late infantile variant CLN5 and CLN7 disease. Accessed August 23, 2021. https://www.clinicaltrials.gov/ct2/show/NCT03822650
ClinicalTrials.gov. Cerliponase alfa observational study in the US. Accessed August 23, 2021. https://clinicaltrials.gov/ct2/show/NCT04476862
ClinicalTrials.gov. Long-term follow up of cln6 batten disease subjects following gene transfer. Accessed August 23, 2021. https://clinicaltrials.gov/ct2/show/NCT04273243
ClinicalTrials.gov. Study for the treatment for CLN7 disease (CLN7). Accessed August 23, 2021. https://clinicaltrials.gov/ct2/show/NCT04737460
ClinicalTrials.gov. UCB transplant of inherited metabolic diseases with administration of intrathecal UCB derived oligodendrocyte-like cells (DUOC-01). Accessed August 23, 2021. https://clinicaltrials.gov/ct2/show/NCT02254863

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Angela Schulz, MD, PhD

Assistant Professor of OB/GYN and Reproductive Biology
Children’s Hospital
NCL Specialty Clinic
International Center of Lysosomal Storage Disorders (ICLD)
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Disclosures

Disclosure: Angela Schulz, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Amicus Therapeutics; BioMarin; Neurogene; REGENXBIO
Grants for clinical research from: BioMarin, REGENXBIO

Editors

Pakinam Aboulsaoud, PharmD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Christina T. Loguidice

Freelance Medical Writer

Disclosures

Disclosure: Christina T. Loguidice has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

Improving Recognition and Awareness of Novel Therapeutics for Batten Disease

Authors: Angela Schulz, MD, PhD
CME Released: 9/21/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/21/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, pediatricians, pediatric neurologists, medical geneticists, and other clinicians who diagnose and treat patients with Batten disease.

The goal of this activity is to improve clinicians’ knowledge of factors that differentiate subtypes of Batten disease and clinical data for therapies being studied for the management of Batten disease.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Factors that differentiate subtypes of Batten disease
- Clinical data for therapies being studied for the management of Batten disease

Disclosures

Faculty

Angela Schulz, MD, PhD

Assistant Professor of OB/GYN and Reproductive Biology
Children’s Hospital
NCL Specialty Clinic
International Center of Lysosomal Storage Disorders (ICLD)
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Disclosures

Disclosure: Angela Schulz, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Amicus Therapeutics; BioMarin; Neurogene; REGENXBIO
Grants for clinical research from: BioMarin, REGENXBIO

Editors

Pakinam Aboulsaoud, PharmD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Christina T. Loguidice

Freelance Medical Writer

Disclosures

Disclosure: Christina T. Loguidice has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

Pre-Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 4

CME Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Angela Schulz, MD, PhD

Editors

Pakinam Aboulsaoud, PharmD

Christina T. Loguidice

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

CME

Improving Recognition and Awareness of Novel Therapeutics for Batten Disease

Target Audience and Goal Statement

Disclosures

Faculty

Angela Schulz, MD, PhD

Editors

Pakinam Aboulsaoud, PharmD

Christina T. Loguidice

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Improving Recognition and Awareness of Novel Therapeutics for Batten Disease

Pre-Assessment Survey